Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Resistance issues with new nucleoside/nucleotide backbone options.

Mark A Wainberg1, Dan Turner

  • 1McGill University AIDS Centre, Montreal, Canada. mark.wainberg@mcgill.ca

Journal of Acquired Immune Deficiency Syndromes (1999)
|August 21, 2004
PubMed
Summary

Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs) are key in HIV therapy. Understanding resistance patterns is crucial for effective combination regimens and preserving future treatment options.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Israeli IBD Research Nucleus: collaborative advancements in Israeli IBD research.

Therapeutic advances in gastroenterology·2026
Same author

Tasty&Healthy Exclusive Whole-Food Diet in Asymptomatic Children and Young Adults With Biologically Active Crohn's Disease: The TASTI-E Randomized Controlled Trial.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

β-Glucan and Inulin Estimated Intake Are Associated With Reduced Risk of Crohn's Disease, Improved Gut Barrier and Systemic Inflammation Markers, and Multi-Omic Signatures in a High-Risk Cohort.

Gastroenterology·2026
Same author

Patient-Reported Outcomes in Clinical Trials of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Interleukin23 Receptor Genetic Variants Associate With Crohn's Disease Risk and Microbiome Changes in Healthy First-Degree Relatives.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus.

Journal of Crohn's & colitis·2026

Area of Science:

  • Virology
  • Pharmacology
  • Infectious Diseases

Background:

  • Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs) are foundational in combination antiretroviral therapy for HIV.
  • Expanding NRTI/NtRTI options necessitate careful consideration of backbone combinations to maximize efficacy and minimize drug resistance.
  • Understanding drug interactions and resistance profiles is critical for optimizing current and future HIV treatment strategies.

Purpose of the Study:

  • To review the clinical implications of resistance profiles associated with current and emerging NRTI/NtRTI regimens.
  • To analyze how novel NRTI/NtRTI combinations impact treatment-emergent drug resistance.
  • To guide clinicians in selecting effective dual NRTI/NtRTI backbones and preserving future therapeutic options.

Main Methods:

Related Experiment Videos

  • Review of clinical trial data on resistance patterns, prevalence, and effects.
  • Analysis of mutation prevalence trends, including M184V, Q151M, L74V, 69 insertions, thymidine analogue mutations, K65R, and Y115F.
  • Evaluation of how specific NRTIs/NtRTIs (e.g., tenofovir DF, abacavir, emtricitabine, zidovudine) select for resistance mutations in various combinations.

Main Results:

  • Prevalence of M184V and Q151M remains stable; L74V, 69 insertions, and thymidine analogue mutations have decreased.
  • Prevalence of K65R and Y115F mutations is increasing, potentially due to new treatment combinations.
  • Tenofovir DF and abacavir-containing regimens select for K65R, with higher frequency observed with tenofovir DF.
  • L74V is more frequent in abacavir-containing regimens but not commonly selected by tenofovir DF.
  • Zidovudine may reduce the risk of L74V and K65R in abacavir- or tenofovir DF-containing regimens.

Conclusions:

  • Emerging resistance patterns necessitate careful selection of dual NRTI/NtRTI backbones.
  • Newer NRTI/NtRTI combinations may increase the selection pressure for specific resistance mutations like K65R.
  • Strategic use of agents like zidovudine might mitigate resistance development in certain NRTI/NtRTI regimens, preserving future treatment options.